127 related articles for article (PubMed ID: 30317630)
21. Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.
Zhang K; Song H; Yang P; Dai X; Li Y; Wang L; Du J; Pan K; Zhang T
Cell Prolif; 2015 Apr; 48(2):249-58. PubMed ID: 25643607
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of histone deacetylation augments dihydrotestosterone induction of androgen receptor levels: an explanation for trichostatin A effects on androgen-induced chromatin remodeling and transcription of the mouse mammary tumor virus promoter.
List HJ; Smith CL; Rodriguez O; Danielsen M; Riegel AT
Exp Cell Res; 1999 Nov; 252(2):471-8. PubMed ID: 10527637
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells.
Makkonen H; Kauhanen M; Jääskeläinen T; Palvimo JJ
Mol Cell Endocrinol; 2011 Jan; 331(1):57-65. PubMed ID: 20728506
[TBL] [Abstract][Full Text] [Related]
25. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
26. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
Chen Y; Bieber MM; Teng NN
Mol Carcinog; 2014 Aug; 53(8):625-34. PubMed ID: 23423781
[TBL] [Abstract][Full Text] [Related]
27. Synthetic paclitaxel-octreotide conjugate reverses the resistance of paclitaxel in A2780/Taxol ovarian cancer cell line.
Shen Y; Zhang XY; Chen X; Fan LL; Ren ML; Wu YP; Chanda K; Jiang SW
Oncol Rep; 2017 Jan; 37(1):219-226. PubMed ID: 27878277
[TBL] [Abstract][Full Text] [Related]
28. Cepharanthine hydrochloride reverses P‑glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway.
Huang CZ; Wang YF; Zhang Y; Peng YM; Liu YX; Ma F; Jiang JH; Wang QD
Oncol Rep; 2017 Oct; 38(4):2558-2564. PubMed ID: 28791369
[TBL] [Abstract][Full Text] [Related]
29. Curcumin reduces paclitaxel resistance in ovarian carcinoma cells by upregulating SNIP1 and inhibiting NFκB activity.
Huang SL; Chang TC; Sun NK
Biochem Pharmacol; 2023 Jun; 212():115581. PubMed ID: 37146834
[TBL] [Abstract][Full Text] [Related]
30. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
[TBL] [Abstract][Full Text] [Related]
32. Nanog interaction with the androgen receptor signaling axis induce ovarian cancer stem cell regulation: studies based on the CRISPR/Cas9 system.
Ling K; Jiang L; Liang S; Kwong J; Yang L; Li Y; PingYin ; Deng Q; Liang Z
J Ovarian Res; 2018 May; 11(1):36. PubMed ID: 29716628
[TBL] [Abstract][Full Text] [Related]
33. 3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function.
Jin L; Yingchun W; Zhujun S; Yinan W; Dongchen W; Hui Y; Xi Y; Wanzhou Z; Buluan Z; Jinhua W
Biomed Pharmacother; 2019 Aug; 116():108992. PubMed ID: 31129513
[TBL] [Abstract][Full Text] [Related]
34. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
[TBL] [Abstract][Full Text] [Related]
35. Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors.
Li N; Chen M; Truong S; Yan C; Buttyan R
Prostate; 2014 Oct; 74(14):1400-10. PubMed ID: 25132524
[TBL] [Abstract][Full Text] [Related]
36. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
37. Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Yamamoto K; Kikuchi Y; Kudoh K; Nagata I
J Cancer Res Clin Oncol; 2000 Mar; 126(3):168-72. PubMed ID: 10741911
[TBL] [Abstract][Full Text] [Related]
38. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
39. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
40. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.
Kang Z; Jänne OA; Palvimo JJ
Mol Endocrinol; 2004 Nov; 18(11):2633-48. PubMed ID: 15308689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
